Skip to main content
Log in

Preoperative Anti-TNF Agents and Morbidity After Ileocolonic Resections in Crohn’s Disease: Are Biologics the Only Ones to Blame?

  • Letter to Editor
  • Published:
Journal of Gastrointestinal Surgery

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kulaylat AN, Kulaylat AS, Schaefer EW, Mirkin K, Tinsley A, Williams E, et al. The Impact of Preoperative Anti-TNFα Therapy on Postoperative Outcomes Following Ileocolectomy in Crohn’s Disease. J Gastrointest Surg 2020. Jan 21. https://doi.org/10.1007/s11605-019-04334-6. Online ahead of print.

  2. Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015;261(3):487–96.

    Article  Google Scholar 

  3. Brouquet A, Maggiori L, Zerbib P, Lefevre JH, Denost Q, Germain A, et al. Anti-TNF Therapy Is Associated with an Increased Risk of Postoperative Morbidity after Surgery for Ileocolonic Crohn Disease: Results of a Prospective Nationwide Cohort. Annals of Surgery. 2018;267(2):221–8.

    Article  Google Scholar 

  4. Cohen B, Fleshner P, Kane S. Anti-tumor necrosis factor is not associated with postoperative infections: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to indentify risk factors for postoperative infections (PUCCINI). Gastroenterology 2019;156(6):S-80.

  5. Quaresma AB, Yamamoto T, Kotze PG. Biologics and surgical outcomes in Crohn’s disease: is there a direct relationship?. Therap Adv Gastroenterol. 2020;Jul16;13:1756284820931738. https://doi.org/10.1177/1756284820931738. eCollection 2020.

  6. Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, et al. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn’s Disease. Dig Dis Sci 2017;62(2):456–64.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paulo Gustavo Kotze.

Ethics declarations

Conflict of Interest

Dr. Queiroz received consulting fees from Janssen, Takeda and Abbvie. Dr. Kotze received consultancy fees and speaking honorarium from Abbvie, Janssen, Pfizer, Takeda, Ferring and Novartis. He also received scientific grants from Takeda and Pfizer. Dr. Perin has no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perin, R.L., Queiroz, N.S.F. & Kotze, P.G. Preoperative Anti-TNF Agents and Morbidity After Ileocolonic Resections in Crohn’s Disease: Are Biologics the Only Ones to Blame?. J Gastrointest Surg 25, 1352–1353 (2021). https://doi.org/10.1007/s11605-021-04976-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-021-04976-5

Navigation